Embera reports positive topline data from Phase Ib cocaine interaction study of EMB-001

US-based clinical-stage pharmaceutical firm Embera NeuroTherapeutics has reported positive topline data from the Phase Ib cocaine interaction study of a patented combination product EMB-001.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news